Equillium, Inc. — Director's Dealing 2020

Apr 24, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Equillium, Inc. (EQ)
CIK: 0001746466
Period of Report: 2020-04-22

Reporting Person: Polu Krishna R (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-22	Stock Option (right to buy)	$3.30	D	208216	Disposed	2028-08-15	Common Stock (208216)	Direct
2020-04-22	Stock Option (right to buy)	$2.45	A	208216	Acquired	2028-08-15	Common Stock (208216)	Direct
2020-04-22	Stock Option (right to buy)	$7.16	D	90000	Disposed	2029-02-12	Common Stock (90000)	Direct
2020-04-22	Stock Option (right to buy)	$2.45	A	90000	Acquired	2029-02-12	Common Stock (90000)	Direct
2020-04-22	Stock Option (right to buy)	$4.75	D	125000	Disposed	2029-12-09	Common Stock (125000)	Direct
2020-04-22	Stock Option (right to buy)	$2.45	A	125000	Acquired	2029-12-09	Common Stock (125000)	Direct

Footnotes

F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.

F2: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.

F3: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.

F4: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.